Save over 35% on Odomzo from Europe.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufactured in Europe by:
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132JH Hoofddorp
Netherlands
Information about Odomzo (Sonidegib)
Odomzo is the brand name for sonidegib, a medication primarily used to treat advanced basal cell carcinoma (BCC), a form of skin cancer. Sonidegib is an oral, hedgehog pathway inhibitor that works by blocking the activity of the hedgehog signaling pathway, which is often abnormally activated in cancer cells and contributes to tumor growth.
Product Highlights
- Odomzo (sonidegib) is an oral medication specifically indicated for the treatment of locally advanced basal cell carcinoma (BCC) in patients who are not candidates for surgery or radiation therapy.
- It is part of a class of drugs known as hedgehog pathway inhibitors, which target the signaling pathways involved in cancer cell growth.
- Sonidegib has been shown to significantly reduce the size of tumors and improve the clinical outcomes in patients with advanced BCC.
Primary Indications for Odomzo (Sonidegib)
- Odomzo is primarily used to treat patients with locally advanced BCC who are not amenable to surgical resection or radiation therapy.
- It may also be used for metastatic BCC, although this indication may vary based on regulatory approvals in different regions.
Key Ingredient
Key Benefits
- Odomzo has been proven to reduce the size of tumors in patients with advanced, inoperable BCC.
- Unlike some other cancer treatments that require intravenous administration, Odomzo is taken as a pill, which may be more convenient for patients.
- Clinical trials have demonstrated that sonidegib can lead to significant tumor shrinkage in patients with locally advanced BCC.
- Some patients may experience long-term disease control and a reduction in tumor burden.
Direction of Use
- The usual recommended dose for Odomzo is 200 mg once daily. It can be taken either with or without food.
- The duration of treatment depends on the patient’s response to the medication and any side effects experienced. The treatment may continue until disease progression or intolerable side effects occur.
Safety Concerns
- Sonidegib can cause birth defects, so it should not be used during pregnancy. Both men and women should use effective contraception during treatment and for a period after discontinuing the drug.
- Common side effects include muscle spasms, bone pain, and joint pain. Patients should promptly notify their healthcare provider if they experience any signs of muscle weakness or discomfort.
- Some patients may experience nausea, diarrhea, or constipation.
- Regular monitoring of liver function is recommended, as sonidegib may cause liver-related issues such as elevated liver enzymes.
- QT prolongation (a heart rhythm issue) has been reported with sonidegib. Patients should be monitored for signs of arrhythmias, especially those with pre-existing heart conditions.
- Fatigue, alopecia (hair loss), and skin rash may occur.
Avoid Odomzo (Sonidegib) If
- You are pregnant or planning to become pregnant, as Odomzo can cause serious harm to the fetus.
- You are breastfeeding, as it is not known if sonidegib passes into breast milk and could harm a nursing infant.
- You have a history of severe liver disease, as sonidegib may exacerbate liver problems.
- You are allergic to sonidegib or any of the other ingredients in Odomzo.
- You have severe heart problems, especially those related to QT prolongation or other cardiac arrhythmias.
